AKT1 and acute lymphoblastic leukemia: Analogously, primary T-ALL xenografts treated with the same combination treatment consisting of the AKT inhibitor MK-2206 and a Cn inhibitor (CsA/CN585/FK-506) showed an enhanced apoptotic response and loss of viability with the combination treatment compared to each single drug only (Figure 6F and Supplementary Figure S3).